Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > “I may have been early, but I’m not wrong.”

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Nov 25, 2022 10:58pm

155 Views

Post# 35129625

RE:“I may have been early, but I’m not wrong.”

The importance of testing could be increasing for viruses.

I've seen a report on CBS that whether a child, adult, or elderly person if they have had COVID the risk for a worse outcome from the other viruses is also increasing.

Here's some data concerning COVID refinfection and the rising risks with repeat infection.